These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6977899)

  • 1. Radioimmunoassay evaluation of anti-C3d reactivity in broad spectrum commercial antiglobulin reagents.
    Chaplin H; Hoffmann NL
    Transfusion; 1982; 22(1):6-11. PubMed ID: 6977899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative quality control of antiglobulin reagents.
    Gardner B; Ghosh S; Brazier DM; Holburn AM
    Clin Lab Haematol; 1983; 5(2):215-29. PubMed ID: 6603958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of pooled polyclonal rabbit anti-human C3d with four monoclonal mouse anti-human C3ds. II. Quantitation of RBC-bound C3d, and characterization of antiglobulin agglutination reactions against RBC from 27 patients with autoimmune hemolytic anemia.
    Chaplin H; Monroe MC
    Vox Sang; 1986; 50(2):87-93. PubMed ID: 2421484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serologic comparison of a monoclonal anti-C3d with commercial antiglobulin reagents.
    Barker JM
    Transfusion; 1982; 22(6):507-10. PubMed ID: 6983162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weak "false positive" direct antiglobulin test reactions with polyspecific antiglobulin reagents: lack of correlation with red-blood-cell-bound C3d.
    Nasongkla M; Hummert J; Chaplin H
    Transfusion; 1982; 22(4):273-5. PubMed ID: 6980507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of red cell bound complement components in development of standards and quality assurance for the anti-complement components of antiglobulin sera.
    Garratty G; Petz LD
    Transfusion; 1976; 16(4):297-306. PubMed ID: 951725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of antibodies to the C3d subcomponent of human C3.
    Chaplin H; Freedman J; Hughes-Jones NC
    Immunology; 1977 Jun; 32(6):1007-15. PubMed ID: 301852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reproducible in vitro preparation of intermediate C3d coated red blood cells.
    Hoffman NL; Monroe MC; Chaplin H
    Transfusion; 1982; 22(3):180-4. PubMed ID: 7046159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification and use of the C3d subunit C3.
    Moore JA; Michael JM; Chaplin H
    Transfusion; 1976; 16(3):200-8. PubMed ID: 1084603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitation of C3 subcomponents on red cells coated with complement in vitro.
    Freedman J; Massey A
    J Clin Pathol; 1980 Oct; 33(10):977-83. PubMed ID: 7430364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epitope specificities and quantitative and serologic aspects of monoclonal complement (C3c and C3d) antibodies.
    Dobbie D; Brazier DM; Gardner B; Holburn AM
    Transfusion; 1987; 27(6):453-9. PubMed ID: 2446405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of fragments of the third component of human complement on erythrocytes by a new immunochemical method.
    Szymanski IO; Odgren PR
    Vox Sang; 1984; 46(2):92-101. PubMed ID: 6608178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The quantification of C3 fragments on erythrocytes: estimation of C3 fragments on normal cells, acquired haemolytic anaemia cases and correlation with agglutination of sensitized cells.
    Merry AH; Thomson EE; Rawlinson VI; Stratton F
    Clin Lab Haematol; 1983; 5(4):387-97. PubMed ID: 6607814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Red blood cell-bound C3d in normal subjects and in random hospital patients.
    Freedman J; Barefoot C
    Transfusion; 1982; 22(6):511-4. PubMed ID: 6216637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. False-positive antiglobulin tests in healthy subjects and in hospital patients.
    Freedman J
    J Clin Pathol; 1979 Oct; 32(10):1014-8. PubMed ID: 521494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further observations on the preparation of antiglobulin reagents reacting with c3d and c4d on red cells.
    Freedman J; Chaplin H; Mollison PL
    Vox Sang; 1977 Jul; 33(1):21-8. PubMed ID: 407724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of monoclonal anti-C3 antibodies to characterise the fragments of C3 that are found on erythrocytes.
    Lachmann PJ; Voak D; Oldroyd RG; Downie DM; Bevan PC
    Vox Sang; 1983; 45(5):367-72. PubMed ID: 6605620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
    Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
    J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Red blood cell-bound C3d in selected hospital patients.
    Freedman J; Ho M; Barefoot C
    Transfusion; 1982; 22(6):515-20. PubMed ID: 6216638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The quantitation of C3d by routine methods after the direct absorption of human plasma with anti-C3c.
    Mlynek Y; Nilsson M
    Acta Pathol Microbiol Immunol Scand C; 1985 Oct; 93(5):195-8. PubMed ID: 3936336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.